Neurology CME Courses
myCME is the premier destination for continuing medical education (CME) and continuing education (CE), committed to providing high-quality, evidence-based, and user-friendly courses tailored to the needs of physicians, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals across 20+ specialties.
Featured below are neurology CME/CE courses available on myCME, including courses from the Neurology Advisor Institute—a specialty CME/CE, clinical news, and information website powered by myCME.
A specialty-based community offering neurology CME/CE courses, resources, and news, centered on you.
NEUROLOGY ADVISOR INSTITUTE SPOTLIGHT COURSE
Talking Curbside: The Pediatric Patient with Narcolepsy or Idiopathic Hypersomnia
Max Credits
0.25 / AMA PRA Category 1 Credits™
0.25 / IPCE Credits
Expires: December 20, 2025
TAKE ME TO THE INSTITUTE
More Neurology CME/CE
01 | Talking Curbside: Narcolepsy or Idiopathic Hypersomnia in a Woman of Childbearing Age
Max Credits
- 0.25 / AMA PRA Category 1 CreditsTM
- 0.25 / IPCE Credits
Expires: December 20, 2025
Program Description
Join Drs. Anne Marie Morse and Lynne Marie Trotti for this unique and exciting Talking Curbside educational series! It’s often difficult to make clinical decisions when we don’t have a lot of guidance, and it’s particularly challenging when our patients present with complex problems. That’s when consultation with an expert is helpful. In this podcast, the experts discuss the approach to managing women of childbearing age who have narcolepsy or idiopathic hypersomnia and require contraception, or alternatively, wish to become pregnant.
Educational Objective
At the conclusion of this activity, participants should be better able to:
- Personalize the management of narcolepsy and idiopathic hypersomnia, taking into account disease burden, comorbidities, and individual patient needs and preferences in women of childbearing age.
Intended Audience
Sleep medicine specialists, neurologists, psychiatrists, pulmonologists, internists, obstetrician-gynecologists, and allied PAs and NPs who diagnose and manage IH and narcolepsy
Commercial Supporters
Supported by educational grants from Avadel CNS Pharmaceuticals, LLC and Takeda Development Centers America, Inc.
02 | Talking Curbside: The Patient with Narcolepsy or Idiopathic Hypersomnia and Comorbid Depression
Max Credits
- 0.25 / AMA PRA Category 1 CreditsTM
- 0.25 / IPCE Credits
Expires: December 20, 2025
Program Description
Join Drs. Anne Marie Morse and Lynne Marie Trotti for this unusual Talking Curbside educational series! It’s sometimes difficult to make clinical decisions when we don’t have a lot of guidance, and it’s particularly challenging when our patients present with complex problems. That’s when consultation with an expert is helpful. In this podcast, the experts discuss management of a patient with a central disorder of hypersomnolence and comorbid depression.
Educational Objective
At the conclusion of this activity, participants should be better able to:
- Personalize management of narcolepsy and idiopathic hypersomnia, taking into account disease burden, comorbidities, and individual patient needs and preferences.
Intended Audience
Sleep medicine specialists, neurologists, psychiatrists, pulmonologists, internists, and allied PAs and NPs who diagnose and manage IH and narcolepsy
Commercial Supporters
Supported by educational grants from Avadel CNS Pharmaceuticals, LLC and Takeda Development Centers America, Inc.
03 | Talking Curbside: Distinguishing Narcolepsy Type 2 from Idiopathic Hypersomnia
Max Credits
0.25 / AMA PRA Category 1 CreditsTM
0.25 / IPCE Credits
Expires: December 20, 2025
GO TO COURSE
MORE DETAILS ▶
Program Description
Distinguishing between idiopathic hypersomnia and narcolepsy Type 2 is challenging. Join Drs. Anne Marie Morse and Lynne Marie Trotti for this unique and exciting Talking Curbside educational series that allows you to get guidance from the experts. In this podcast, the experts discuss practical approaches to distinguishing and managing Narcolepsy Type 2 and Idiopathic Hypersomnia.
Educational Objectives
At the conclusion of this activity, participants should be better able to:
- Diagnose idiopathic hypersomnia and narcolepsy using appropriate history taking, sleep diaries, questionnaires, and objective tests.
- Personalize management of narcolepsy and idiopathic hypersomnia, taking into account disease burden, comorbidities, and individual patient needs and preferences.
Intended Audience
Sleep medicine specialists, neurologists, psychiatrists, pulmonologists, internists, and allied PAs and NPs who diagnose and manage IH and narcolepsy
Commercial Supporters
Supported by educational grants from Avadel CNS Pharmaceuticals, LLC and Takeda Development Centers America, Inc.
Max Credits
0.25 / AMA PRA Category 1 CreditsTM
0.25 / IPCE Credits
Expires: December 20, 2025
GO TO COURSE
04 | Talking Curbside: Managing Complex Symptoms in Narcolepsy and Idiopathic Hypersomnia
Max Credits
0.25 / AMA PRA Category 1 CreditsTM
0.25 / IPCE Credits
Expires: December 20, 2025
MORE DETAILS ▶
Program Description
Managing symptoms of narcolepsy and idiopathic hypersomnia outside of excessive daytime sleepiness and cataplexy is poorly researched and presents numerous challenges in clinical practice. Join Drs. Anne Marie Morse and Lynne Marie Trotti for this unique and exciting Talking Curbside educational series that allows you to ask specific questions about your patients and get guidance from the experts. In this podcast, the experts discuss how to manage difficult-to-treat symptoms of narcolepsy and idiopathic hypersomnia such as REM-behavior disorders, disrupted nocturnal sleep, sleep inertia, dysautonomia, and more…
Educational Objective
At the conclusion of this activity, participants should be better able to:
- Personalize management of narcolepsy and idiopathic hypersomnia, taking into account disease burden, comorbidities, and individual patient needs and preferences.
Intended Audience
Sleep medicine specialists, neurologists, psychiatrists, pulmonologists, internists, and allied PAs and NPs who diagnose and manage IH and narcolepsy
Commercial Supporters
Supported by educational grants from Avadel CNS Pharmaceuticals, LLC and Takeda Development Centers America, Inc.
Max Credits
0.25 / AMA PRA Category 1 CreditsTM
0.25 / IPCE Credits
Expires: December 20, 2025
GO TO COURSE
05 | Not All Amyloid Proteins Are Alike – Podcast 1
MORE DETAILS ▶
Program Description
In this first installment of a series of podcasts titled, The New Era of Anti-Amyloid Therapy in Alzheimer’s Disease: Targeting and Timing Are Everything, memory disorders experts Dr. Anna D. Burke and Dr. Dani Cabral tease apart the different forms of the protein amyloid beta, a major hallmark of Alzheimer’s disease, and describe their pathologic significance. Implications for the efficacy and safety of new amyloid-targeting therapies are also discussed with respect to their affinities for different amyloid species.
Educational Objective
At the conclusion of this activity, participants should be better able to:
- Describe soluble and insoluble forms of amyloid beta and how they contribute to neuronal dysfunction and injury in the pathologic trajectory of Alzheimer’s disease.
Intended Audience
The primary target audiences are physicians (MDs/DOs), nurse practitioners (NPs), and physician assistants (PAs) in neurology, geriatric psychiatry, psychiatry, and geriatric medicine. The secondary target audience comprises primary care physicians, NPs, and PAs.
Commercial Supporter
Supported by an educational grant from Eisai, Inc.
Max Credits
0.25 / AMA PRA Category 1 CreditsTM
Expires: May 12, 2026
GO TO COURSE
06 | Lessons From Study Designs for Available Anti-Aβ mAbs – Podcast 2
MORE DETAILS ▶
Program Description
Pivotal trials for newly available anti-amyloid therapies for mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease differ in a number of important ways that inform therapy selection and expected outcomes. In this second episode of their podcast series — The New Era of Anti-Amyloid Therapy in Alzheimer’s Disease: Targeting and Timing Are Everything — memory disorders experts Dr. Anna D. Burke and Dr. Dani Cabral consider these differences and discuss how they identify candidates for therapy, how they select a specific treatment, and how they set expectations with patients and their caregivers.
Educational Objective
At the conclusion of this activity, participants should be better able to:
- Employ efficacy and safety data from pivotal clinical trials of anti-amyloid therapies, including data from lower-tau subgroups, to make treatment decisions, and set appropriate patient expectations.
Intended Audience
The primary target audiences are physicians (MDs/DOs), nurse practitioners (NPs), and physician assistants (PAs) in neurology, geriatric psychiatry, psychiatry, and geriatric medicine. The secondary target audience comprises primary care physicians, NPs, and PAs.
Commercial Supporter
Supported by an educational grant from Eisai, Inc.
Max Credits
0.50 / AMA PRA Category 1 CreditsTM
Expires: May 12, 2026
GO TO COURSE
07 | Anti-Aβ Maintenance Therapy in MCI and Mild Dementia Due to Alzheimer’s Disease – Podcast 3
MORE DETAILS ▶
Program Description
Alzheimer’s experts Dr. Anna D. Burke and Dr. Dani Cabral kick off the third episode of their podcast series — The New Era of Anti-Amyloid Therapy in Alzheimer’s Disease: Targeting and Timing Are Everything — by considering evidence for using maintenance anti-amyloid therapy after initial treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease. In this installment, they discuss the recent availability of a new monthly formulation of an anti-amyloid drug for maintenance treatment and prospects for a subcutaneous therapy in late-phase development.
Educational Objective
At the conclusion of this activity, participants should be better able to:
- Apply clinical data to support the use of maintenance therapy with amyloid-targeting agents in mild cognitive impairment and mild Alzheimer’s disease.
Intended Audience
The primary target audiences are physicians (MDs/DOs), nurse practitioners (NPs), and physician assistants (PAs) in neurology, geriatric psychiatry, psychiatry, and geriatric medicine. The secondary target audience comprises primary care physicians, NPs, and PAs.
Commercial Supporter
Supported by an educational grant from Eisai, Inc.
Max Credits
0.25 / AMA PRA Category 1 CreditsTM
Expires: May 15, 2026
GO TO COURSE
Click to see myCME’s full catalog of free neurology CME/CE courses.
